TransMedics Group (NASDAQ:TMDX) Price Target Raised to $130.00

Key Points

• Stifel Nicolaus raised its price target on TransMedics to $130 (from $115) while maintaining a "hold" rating, which implies only about a 0.15% upside from the current price.
• Several other firms have set materially higher targets (Oppenheimer and Needham up to $175 and $174), leaving a MarketBeat consensus average target of $152.33 and an overall consensus rating of "Moderate Buy" (six Buys, five Holds).
• The stock is trading down (reported down 7.3%, opened at $129.80) and has seen notable insider selling—including the CFO selling 7,236 shares (~$1.07M)—with insiders offloading 16,205 shares (~$2.35M) over the past three months while insiders still own ~7% of the company.

TransMedics Group (NASDAQ:TMDX - Get Free Report) had its price target upped by analysts at Stifel Nicolaus from $115.00 to $130.00 in a report released on Monday,Benzinga reports. The brokerage presently has a "hold" rating on the stock. Stifel Nicolaus' price objective would suggest a potential upside of 0.15% from the company's current price.

TMDX has been the subject of a number of other research reports. Oppenheimer raised their price target on shares of TransMedics Group from $150.00 to $175.00 and gave the stock an "outperform" rating in a report on Wednesday, February 25th. Wall Street Zen downgraded shares of TransMedics Group from a "buy" rating to a "hold" rating in a research note on Saturday, February 28th. Canaccord Genuity Group lifted their target price on TransMedics Group from $147.00 to $148.00 and gave the company a "buy" rating in a report on Wednesday, December 17th. Morgan Stanley increased their price objective on TransMedics Group from $123.00 to $135.00 and gave the company an "equal weight" rating in a report on Tuesday, December 2nd. Finally, Needham & Company LLC boosted their price target on shares of TransMedics Group from $166.00 to $174.00 and gave the company a "buy" rating in a research report on Wednesday, February 25th. Six investment analysts have rated the stock with a Buy rating and five have assigned a Hold rating to the company's stock. According to data from MarketBeat, TransMedics Group currently has a consensus rating of "Moderate Buy" and an average target price of $152.33.

TransMedics Group Trading Down 7.3%

TMDX opened at $129.80 on Monday. The firm has a market capitalization of $4.45 billion, a price-to-earnings ratio of 26.49 and a beta of 1.98. The company's 50 day simple moving average is $135.35 and its two-hundred day simple moving average is $126.96. TransMedics Group has a 1-year low of $62.23 and a 1-year high of $156.00. The company has a debt-to-equity ratio of 1.06, a current ratio of 7.14 and a quick ratio of 6.59.

Insider Buying and Selling at TransMedics Group

In related news, CFO Gerardo Hernandez sold 7,236 shares of the stock in a transaction on Wednesday, March 4th. The stock was sold at an average price of $147.21, for a total transaction of $1,065,211.56. Following the completion of the sale, the chief financial officer directly owned 14,689 shares of the company's stock, valued at $2,162,367.69. This trade represents a 33.00% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Also, insider Anil P. Ranganath sold 864 shares of the firm's stock in a transaction that occurred on Monday, March 2nd. The shares were sold at an average price of $139.12, for a total value of $120,199.68. Following the completion of the transaction, the insider directly owned 13,091 shares of the company's stock, valued at $1,821,219.92. The trade was a 6.19% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Over the last three months, insiders have sold 16,205 shares of company stock valued at $2,353,002. Corporate insiders own 7.00% of the company's stock.

Institutional Trading of TransMedics Group

Several large investors have recently modified their holdings of TMDX. Pacer Advisors Inc. purchased a new stake in TransMedics Group in the 4th quarter valued at about $162,000. Virtu Financial LLC grew its holdings in TransMedics Group by 467.7% in the fourth quarter. Virtu Financial LLC now owns 26,949 shares of the company's stock valued at $3,278,000 after purchasing an additional 22,202 shares during the period. Corient Private Wealth LLC increased its position in TransMedics Group by 32.5% during the fourth quarter. Corient Private Wealth LLC now owns 3,084 shares of the company's stock worth $375,000 after purchasing an additional 757 shares during the last quarter. Summit Global Investments raised its stake in TransMedics Group by 3.6% during the fourth quarter. Summit Global Investments now owns 3,260 shares of the company's stock worth $397,000 after purchasing an additional 112 shares during the period. Finally, EP Wealth Advisors LLC purchased a new position in TransMedics Group during the fourth quarter worth approximately $210,000. 99.67% of the stock is currently owned by institutional investors and hedge funds.

TransMedics Group Company Profile

TransMedics Group, Inc is a medical device company headquartered in Andover, Massachusetts, that specializes in advanced organ preservation and transport systems for transplantation. The company's flagship technology, the Organ Care System (OCS), maintains donor organs in a near-physiologic, warm, beating state during transportation, with the aim of extending preservation times and improving post‐transplant outcomes. TransMedics' solutions address a critical need in transplantation by reducing ischemic injury and expanding the donor organ pool.

TransMedics currently markets two commercially available OCS platforms.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.